Dave Ricks, CEO of Eli Lilly: How a 150 Year Old Company Keeps Winning

ELI5/TLDR

Eli Lilly is 150 years old and is now the most valuable healthcare company on the planet, mostly because it bet early and broadly on the same family of hormones that power Ozempic, Mounjaro and Zepbound. CEO Dave Ricks thinks the obesity market is barely scratched — maybe 20-30 million people on these drugs today, versus a billion-plus who qualify — and that, unlike most medicines, cutting the price here grows the business rather than shrinking it. He has a stack of next-generation drugs lined up (a pill, a triple hormone, an amylin drug with almost no nausea), is selling a third of US obesity prescriptions straight to consumers through a website, and thinks these same drugs may eventually matter for inflammation, addiction, dementia and even cancer prevention. The through-line for 150 years, he says, is being relentlessly scientific and keeping leaders around long enough to learn from failure.

The Full Story

The durability question

The interview opens on the obvious puzzle: how does a drug company last 150 years and end up on top, when the business is built on patents that expire and bets that mostly fail. Ricks gives three through-lines. First, a hard scientific orientation baked in from the founding — Colonel Eli Lilly fought in the Civil War, saw that most medicines were “made up,” with no evidence and no quality, and his very first hire was a real trained chemist. Second, an unusually long-tenured workforce in a business with long cycles.

“To actually see a full cycle of a medicine, see failure and learn from it and iterate and improve. That’s the core, I think, to success. Most things don’t work the first time and if you’re just chasing the next wave, I don’t think you actually really understand how the business works.”

Third, continuity at the top. Ricks is only the 12th CEO in the company’s history — “that’s one less than popes in that period of time” — which buys the long-horizon thinking he thinks the sector demands. The counterweight is adaptability: when Lilly has stumbled, it was because it failed to adapt to new science and methods.

Speeding up the drill

Lilly went through a rough patent-cliff stretch before Ricks joined the leadership team, and the company’s response was to rediscover its “soul” — organic R&D. Under Ricks the project has been to take good and make it great, largely by getting faster. A program started around 2013-14 aimed to halve development time. Back then Lilly took about 11 years from IND (the regulatory green light to start human testing) to FDA approval; the industry averaged ten. The industry has since come down to eight or nine. Lilly is at “six and change.” Crucially, he says this isn’t a trick of shifting toward inherently faster disease areas — they materially sped up the slow stuff, cardiometabolic and oncology.

Why obesity is not a normal drug market

A billion people globally have obesity; one report Ricks cites projects four billion by 2035. His framing of the underlying cause is almost anthropological:

“We evolved as organisms… we evolved in a world of scarcity. We don’t really have that many defenses against abundant food to kind of keep us in homeostasis. One of them is incretins and GLP-1s. So that’s what we’ve harnessed.”

A quick chaperone on the biology, since the whole company now rests on it. Incretins are gut hormones the body releases when you eat; they nudge insulin, slow the stomach, and dial down appetite. GLP-1 is the famous one. The breakthrough drugs (semaglutide, Lilly’s tirzepatide) are engineered, longer-acting copies of these hormones. Ricks describes two insights that cracked the category open. One: with a “flat” drug — steady levels rather than sharp peaks and troughs — you can push the dose up to get the weight-loss benefit without the nausea and vomiting that killed the early versions. Two, and bigger: GLP-1 is not alone. It belongs to a “super family” of related hormones that work synergistically. Tirzepatide hits two of them, GLP-1 and GIP, and the GIP component both adds its own weight-loss effect and quiets the gut side effects — more efficacy, fewer side effects, which is what makes a blockbuster.

This matters strategically because of a contrast Ricks draws with cancer’s checkpoint inhibitors. There, everyone hypothesized a whole class of drugs, but really only one target (PD-1) panned out. In obesity, it genuinely isn’t just GLP-1 — amylin works, glucagon works. Lilly read that early and “best cover every square,” building a drug against each hormone in the family. The payoff: “pretty much every one of these ideas that’s working, we have a medicine for and with maybe one exception, we have the first one.”

The pipeline, drug by drug

Ricks walks through the wave behind the current cash cows (Zepbound for obesity, Mounjaro for diabetes — same molecule, two names).

Orforglipron is the oral GLP-1 pill. Ricks expects it to be huge “not because of the efficacy but because of reach” — cheaper, manufacturable at global scale, good enough to get most people their 30 pounds. The maintenance and mass-market workhorse.

Retatrutide is the triple agonist (GLP-1 + GIP + glucagon) and the one Silicon Valley is buzzing about, with a grey market of off-label Chinese knockoffs (“we don’t recommend this”). It produces such profound weight loss that the number-one dropout reason in trials was losing too much weight. Glucagon’s particular trick is depleting visceral fat — the dangerous fat under the stomach wall, bad for liver, kidney and heart — and also, bluntly, giving people the flat stomach they want. The trade-off is more side effects, so it is positioned as a higher-BMI, doctor-supervised product rather than casual self-care.

Eloralintide is the amylin drug, and the one Ricks personally likes most. Amylin is another super-family hormone. The clever engineering bit: other amylin drugs hit a shared calcitonin receptor that causes GI distress; Lilly “dialed that out” to get a pure, selective amylin drug — “almost 20% weight loss and almost no GI side effects” with no painful titration ramp.

His punchline on which one wins: “we don’t have to care which one gets really big… if it says Lilly on it, we’re good.”

On the once-monthly dosing race some competitors are running, Ricks is pointedly skeptical. He argues the published half-lives suggest these aren’t truly monthly — by day 30 you’re down to ~20% of the dose, you re-dose, and you restart the nausea-titration curve every month, sacrificing efficacy. He thinks the convenience returns diminish fast (monthly beats weekly; two months barely beats one) and that Lilly has flatter-profile ideas it simply chooses not to disclose.

Lilly Direct: a manufacturer selling straight to you

Launched January 2024, Lilly Direct now carries roughly a third of all US obesity business and over half of new Zepbound prescriptions. Ricks frames it as an accidental product-market fit — his predecessor’s parting advice was literally “never be in retail” — that turned into a strategic asset. The benefits stack up: more reach and sales; first-party, real-time data on what consumers buy and complain about; a price-discipline benchmark that stops middlemen markups; an owned route to market as healthcare reorganizes itself; and, importantly, discretion. People with obesity have often “doctor shopped” and been handed a useless diet sheet, and they report stigma at the pharmacy counter. Buying online sidesteps both.

He sees the model going global — already live in the UK, and a store-within-a-store on JD and Alibaba in China. Outside the US, where the medical referral chain is more “choked off,” he expects an even higher share to go online. He is candid that the tech is duct-tape-and-baling-wire today, on “version 2.0,” with auto-renewal by SMS but a long way from Amazon-grade e-commerce.

The deeper bet is that Lilly Direct is a capability, not just a channel — a way to deliver future preventative medicines (he name-checks siRNA gene-silencing drugs for things like Lp(a), a genetic heart-risk factor a third of adults carry) directly, cheaply, and at volume, outside the traditional payment system.

Pricing: the heretical claim

The investor fear is that GLP-1 prices fall forever with no floor. Ricks counters with the central, unusual bet: this market has price elasticity, unlike normal drug markets where cutting price cuts cash flow one-for-one.

“Price down equals cash flow down 1 to 1. That is not what happens here. Actually I think we’re seeing growth acceleration with price cuts. So that’s acting more like a consumer market.”

The move from ~$1,000/month to ~$350 was “mostly positive” — partly because Lilly was already netting roughly that in diabetes, so it was less a concession than a volume expansion into the cash channel. What keeps a floor under prices, he argues, is innovation: newer drugs launch at a premium and then decay, so a steady stream of better drugs (eloralintide, retatrutide, orforglipron) keeps resetting the starting point higher. He also notes a self-discipline point for competitors: if you have a better drug in your own pipeline, crushing the price of your current one is foolish, because you’ll have to undercut yourself.

Compounders, the FDA, and snake oil

Ricks is exasperated by the persistence of compounded copies (and Hims’ attempt at an oral Wegovy). He concedes the cannibalization is small — maybe a couple hundred thousand on compounded tirzepatide — but the policy precedent frightens him: if anyone can copy your drug without doing the work, the incentive to invest in R&D collapses. He ties it straight back to why the FDA exists, and to Lilly’s own founding against “snake oil.”

The safety case is vivid: when Lilly tests product bought online, a meaningful fraction doesn’t even contain tirzepatide, and some has errors in the amino acid sequence. Worse, the common trick of mixing it with vitamin B12 to skirt compounding rules forms “a new complex molecule that’s not tirzepatide. Never been tested in man, although except for the people taking it today.” And the kicker on how hard this is to get right:

“The tirzepatide is, I think, series number 7,023, which means we made 7,022 other versions of tirzepatide we threw away.”

He expects a federal access expansion (part of an MFN — most-favored-nation — pricing deal with the Trump administration) bringing Zepbound to as low as $50 to simply kill the compounding economics: “There’s nobody using compounding who’s going to use compounding when they get $50 Zepbound.”

Beyond obesity: inflammation, the brain, cancer

The same drugs may matter well outside weight loss. On inflammation: a Taltz-plus-Zepbound study showed arthritis and psoriasis benefits arriving before the weight loss, with the inflammation marker CRP dropping within a week — evidence of a direct anti-inflammatory mechanism. Retatrutide produced the biggest osteoarthritis pain improvement ever recorded on the WOMAC scale.

On the brain: more speculative, and Ricks flags the risk honestly — a competitor’s big Alzheimer’s program moved biomarkers but not outcomes. He’s more bullish on vascular dementia and intrigued by anecdotal signals on addictive/hedonic behaviors (smoking, drug abuse, even gambling and online shopping). The one he’d call a true home run: large retrospective databases (notably a VA study) show big outcome shifts in schizophrenia, bipolar and major depression among people who happened to be on GLP-1s. “We better figure that out.”

On cancer: hard to study as prevention, but obese populations have meaningfully higher cancer rates, and he’d be “personally surprised if we don’t wake up in five years and see cancer surveillance rates dropping.”

The rest of the business and M&A

Ricks is careful to note the non-obesity base business still grows mid-teens and would rank top-three in the industry on its own. Oncology is the most mature piece — four phase-three programs, with the oral SERD imlunestrant (a degrader that destroys the estrogen receptor rather than just blocking it) the big one. Neuroscience he sees as the highest-upside area, citing the Alzheimer’s prevention study (treating amyloid-positive but symptom-free patients identified by a simple blood test, p-tau217, rather than a brain scan) and a fresh deal with Centessa on the orexin sleep/wake pathway.

On M&A, Lilly has shifted to a constant, systematic “string of pearls” — about 40 deals last year, “way more than anyone else,” but only the 10th-most capital deployed: many small, cheap bets rather than megamergers (the biggest ever was Loxo at $8bn; Centessa at ~$6bn is large for them). The logic is that the industry has ~20 scaled legacy players and ~500 biotechs with a thin middle, so transformative mergers are scarce; value comes from buying earlier, before the data is obvious to everyone. Going forward he expects to widen the therapeutic aperture and lift deal sizes, because Lilly wants to be priced like a growth stock and not coast to a terminal GLP-1 state.

What makes him tick

Asked the podcast’s title question, Ricks gives three layers: loyalty “to a fault” (30 years at Lilly), a genuinely competitive streak (“I like to win a lot, and I don’t find a lot of satisfaction in coming in second” — board games at his kitchen table were “war”), and a founding personal moment. He only joined Lilly because his then-fiancée was at med school in Indianapolis; early in his career he brought a drug into the company via business development, took it through phase three, launched it — and then his own mother was diagnosed with that very disease and treated with that very Lilly medicine. “That’s why we’re here.”

His ten-year vision rests on three things: prove incretins are like antibiotics, not PD-1s — a foundational category that makes a new era of medicine possible (Lilly marketed penicillin and invented vancomycin); build the rest of the business with the same R&D engine, while having the humility to say “we tried and failed” and buy back stock if needed; and leave behind leaders who “really own the customer and love innovation.”

“We connect science to people with problems, and if you can see both sides clearly… then you can be a great leader in this industry.”

Key Takeaways

The category is barely penetrated. ~20 million on these drugs globally today, headed to ~30 million “this year”; ~1 billion qualify. Developed-market theoretical penetration is still low single digits, versus 20-40% for mature chronic-disease drugs like statins. 100 million patients is explicitly “achievable.”
Obesity drugs have price elasticity — the central, contrarian bet. Cutting price grows revenue here (“growth acceleration with price cuts”), unlike normal drugs where it’s 1:1 down. The $1,000 → ~$350/month move was net positive.
The science is a hormone “super family,” not one target. GLP-1 + GIP = tirzepatide (Zepbound/Mounjaro). Add glucagon = retatrutide. Amylin = eloralintide. Lilly built a drug for each square and usually got there first.
“Flat” pharmacokinetics is the whole trick — steady drug levels let you raise the dose for efficacy without triggering nausea. Ricks dismisses rivals’ “monthly” shots as not truly flat-for-a-month, forcing a side-effect restart each cycle.
Eloralintide (amylin) is engineered to skip the calcitonin receptor that causes GI side effects → ~20% weight loss, almost no nausea, no titration ramp. Ricks’s personal favorite.
Retatrutide (triple agonist) is so potent that “lost too much weight” was the top trial dropout reason; glucagon strips visceral fat. Positioned for high BMI under supervision; big off-label grey market in San Francisco.
Orforglipron (oral pill) wins on reach and price, not peak efficacy — the global mass-market maintenance drug.
Lilly Direct (launched Jan 2024) = ~1/3 of US obesity business, >50% of new Zepbound scripts. Benefits: reach, first-party consumer data, price discipline, owned channel, and discretion (avoiding pharmacy-counter stigma). Now expanding to UK and China (JD/Alibaba); expected to be even bigger share outside the US.
R&D speed: Lilly is at ~6 years IND-to-approval vs industry ~8-9 and its own historical 11; the speed-up held across slow areas (oncology, cardiometabolic), not just easy ones.
Compounding is a small revenue threat but a large policy threat. Tested online product often lacks tirzepatide or has sequence errors; B12 mixing creates an untested new molecule. A planned ~$50 Zepbound (via an MFN deal with the Trump administration) is expected to kill compounding economics.
Tirzepatide was molecule #7,023 — 7,022 discarded versions to find one with the right properties. Ricks’s argument for why copying is reckless.
GLP-1s show signal well beyond weight: anti-inflammatory (CRP drops in a week; record OA pain improvement), addiction/hedonic behaviors, and big retrospective outcome shifts in schizophrenia/bipolar/depression. Cancer prevention is plausible but very hard to prove.
M&A = “string of pearls”: ~40 small deals last year (most in industry by count, 10th by capital). Biggest deal ever was Loxo at $8bn. Strategy: buy early before data is public; widen therapeutic aperture; lift deal sizes to stay a growth stock.
Base (non-obesity) business still grows mid-teens and would rank top-three in pharma standalone. Oncology bet: imlunestrant, an oral SERD “degrader.” Neuroscience seen as highest upside (Alzheimer’s prevention via p-tau217 blood test; Centessa orexin deal).
Governance/culture: 12th CEO in 150 years; long employee tenure as a moat in a long-cycle business; Indianapolis/Midwest “no fuss” ethos.

Claude’s Take

This is a genuinely good interview, but it’s worth naming what it is: a friendly conversation between a CEO and an investor (Mike Rockefeller of Woodline) who is long the stock and clearly admires it. There are no hard adversarial questions. So treat every number and claim as the most flattering true version.

That said, Ricks is unusually substantive for a CEO. He doesn’t dodge into platitudes; he explains the actual pharmacology, names the trade-offs (retatrutide’s side effects, the brain-health risk, the compounding cannibalization being real if small), and makes a falsifiable central claim — that this market has price elasticity — that he knows investors are betting against. That’s the most important and most contestable idea in the whole hour. If he’s right, the bear case (prices race to zero, margins evaporate) is wrong; if he’s wrong, a lot of Lilly’s valuation is. He offers evidence (volume accelerating as price fell to $350) but it’s early and self-reported.

The strongest material is the strategic logic: the “cover every square” bet on the hormone super-family, the flat-PK insight, and the Lilly-Direct-as-capability framing are real, durable advantages that explain how a 150-year-old company ended up most valuable. The weakest material is the speculative beyond-obesity stuff — inflammation, dementia, addiction, cancer — where the retrospective-database signals are intriguing but exactly the kind of correlation that often evaporates in a controlled trial (he half-admits this with the competitor’s failed Alzheimer’s outcomes). The “antibiotics, not PD-1s” analogy is a nice rhetorical frame and also an unproven thesis dressed as history.

Scoring it an 8: high information density, the CEO actually teaches the science and the business model rather than spinning, and the central elasticity claim is a sharp, testable idea you’ll remember. Docked from higher because the format is uncritical and the most exciting claims (the price floor, the new indications) are bets, not facts — you’re getting the bull case articulated extremely well, not a balanced view.